<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02749617</url>
  </required_header>
  <id_info>
    <org_study_id>H14-01652</org_study_id>
    <nct_id>NCT02749617</nct_id>
  </id_info>
  <brief_title>A Pilot Study Investigating Apixaban and Dexamethasone InterAction in Multiple Myeloma</brief_title>
  <acronym>ADAM</acronym>
  <official_title>A Pilot Study Investigating Apixaban and Dexamethasone InterAction in Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study will investigate the impact of dexamethasone (DEX) on anti-Xa levels in&#xD;
      participants taking apixaban 2.5 mg twice a day by mouth (PO BID). Investigators propose a&#xD;
      prospective, cohort study of 24 participants with multiple myeloma, in whom a&#xD;
      lenalidomide-dexamethasone (LEN-DEX)-based myeloma treatment regimen is indicated. Eligible&#xD;
      participants will initiate thromboprophylaxis with apixaban prior to starting their&#xD;
      DEX-containing regimen and continue until the end of cycle 3. Anti-Xa levels, D-Dimer and&#xD;
      plasma drug concentration will be measured.&#xD;
&#xD;
      This pilot study looks to investigate this potential interaction between apixaban and&#xD;
      dexamethasone to see if it warrants further investigation in a larger study.&#xD;
&#xD;
      The sample size of 24 provides 90% power to detect a primary outcome of ≥ 50% reduction in&#xD;
      peak anti-Xa levels from baseline. Secondary outcomes include changes in plasma apixaban&#xD;
      levels, D-dimer, and symptomatic venous thromboembolism (VTE) and bleeding during a 3-month&#xD;
      treatment period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study has terminated due to poor enrollment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was stopped due to lack of enrollment.&#xD;
  </why_stopped>
  <start_date type="Actual">August 9, 2016</start_date>
  <completion_date type="Actual">March 28, 2019</completion_date>
  <primary_completion_date type="Actual">January 3, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti Xa Activity</measure>
    <time_frame>3 months</time_frame>
    <description>serial anti Xa activity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Apixaban Levels</measure>
    <time_frame>3 months</time_frame>
    <description>Due to lack of enrollment, plasma apixaban levels were not analyzed</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Anti-Xa Activity</condition>
  <arm_group>
    <arm_group_label>apixaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>apixaban 2.5 mg PO BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>apixaban</intervention_name>
    <description>2.5 mg PO BID</description>
    <arm_group_label>apixaban</arm_group_label>
    <other_name>Eliquis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with diagnosis of multiple myeloma according to criteria of the International&#xD;
             Myeloma Working Group&#xD;
&#xD;
          -  Patients in whom a LEN-DEX-based treatment regimen is indicated&#xD;
&#xD;
          -  Adult patients ≥ 19 years of age who are able to freely provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concomitant antiplatelet or anticoagulant use&#xD;
&#xD;
          -  Calculated creatinine clearance &lt; 30 mL/min by Cockcroft-Gault formula&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 3 times upper&#xD;
             limit of normal (ULN)&#xD;
&#xD;
          -  Total bilirubin &gt; 2 x ULN&#xD;
&#xD;
          -  Thrombocytopenia &lt; 50 x 10 gigalitres (Gl)&#xD;
&#xD;
          -  High bleeding risk or spontaneously prolonged prothrombin time or activated partial&#xD;
             thromboplastin time &gt; 1.5 x ULN&#xD;
&#xD;
          -  Body weight &lt;50 or &gt;120 kg&#xD;
&#xD;
          -  Concomitant use of CYP3A4 or p-glycoprotein inducers or inhibitors&#xD;
&#xD;
          -  Use of Ginkgo biloba or St. John's Wort within 14 days before first dose of study drug&#xD;
&#xD;
          -  Dexamethasone use within last 3 months&#xD;
&#xD;
          -  Women of Childbearing potential without proper contraceptive measures, pregnancy or&#xD;
             breast feeding&#xD;
&#xD;
          -  Life expectancy less than 3 months&#xD;
&#xD;
          -  Inability to swallow or issues with malabsorption&#xD;
&#xD;
          -  Any other medical, social, logistical, geographical or psychological factors, which in&#xD;
             the opinion of the investigator, would prohibit follow-up, compliance and study&#xD;
             completion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agnes YY Lee, MD MSc FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia, Division of Hematology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 30, 2016</study_first_submitted>
  <study_first_submitted_qc>April 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2016</study_first_posted>
  <results_first_submitted>July 28, 2021</results_first_submitted>
  <results_first_submitted_qc>July 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 23, 2021</results_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Agnes Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 30, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT02749617/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Apixaban</title>
          <description>apixaban 2.5 mg PO BID&#xD;
apixaban: 2.5 mg PO BID</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Apixaban</title>
          <description>apixaban 2.5 mg PO BID&#xD;
apixaban: 2.5 mg PO BID</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Anti Xa Activity</title>
        <description>serial anti Xa activity</description>
        <time_frame>3 months</time_frame>
        <population>Lack of data.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>apixaban 2.5 mg PO BID&#xD;
apixaban: 2.5 mg PO BID</description>
          </group>
        </group_list>
        <measure>
          <title>Anti Xa Activity</title>
          <description>serial anti Xa activity</description>
          <population>Lack of data.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Apixaban Levels</title>
        <description>Due to lack of enrollment, plasma apixaban levels were not analyzed</description>
        <time_frame>3 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Apixaban</title>
          <description>apixaban 2.5 mg PO BID&#xD;
apixaban: 2.5 mg PO BID</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Nose Bleed</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Flu-like Symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pseudomonas aerugionosa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Skin Itchiness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Low Energy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Back right-sided buttock pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of HRP</name_or_title>
      <organization>Hematology Research Program (HRP)</organization>
      <phone>6048754111 ext 22958</phone>
      <email>alee14@bccancer.bc.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

